Orphan Drug Pipeline & Regulatory Insight 2025

Orphan Drug Pipeline & Regulatory Insight 2025" Report Highlights:


Global Orphan Drug Market Overview: US$ 260 Billion Opportunity

Global Orphan Drug market by Segment

Regulatory Landscape: USA, Europe & Asia

Orphan Drug Designation & Reimbursement Policy: USA, Europe & Asia

Global Orphan Drug Clinical Pipeline Insight: 973 Drugs

Marketed Orphan Drug Clinical Insight: 366 Drugs


The global orphan drug market opportunity is expected to surpass US$ 260 Billion by 2025 as per recent research report "Global Orphan Drug Pipeline & Regulatory Insight 2025" published by PNS Pharma. The orphan drug segment has emerged as a new growth frontier for pharmaceutical companies faced with issues like patent expiry, competition from generics and biosimilars, exhausting pipelines and stringent regulatory and policy framework. Increasing investment in clinical research and rapid commercialization of orphan drugs has resulted in the paradigm shift in operational strategy of pharmaceutical companies. In past, pharmaceutical companies were more focused on the research and development of essential medicines leading to high competition levels and low financial margins.

The exponential growth in global orphan drug market is driven by favorable regulatory and policy framework, increasing research and developmental activities, high ROI rates , government incentives for drug developmental, market exclusivity along with strong support from FDA and EU Commission in special protocols. The research and developmental activities for orphan drugs have also received impetus thrust from the pharmaceutical companies efforts to overcome the impact of revenue loss due the patent expiry of blockbuster drugs.

In terms of therapeutic application, oncology has been predominant segment in the global orphan drug market landscape followed neurology, rheumatology, hematology, infectious diseases and others. Currently, more than 200 companies are partnering for research and development of more than 300 orphan designated drugs in oncology segment. Oncology, as a therapeutic area has also transformed from evolution to customized or precision medicine in the pharmaceutical industry. Utilizing biomarkers to develop targeted treatments and therapies is an approach which is being increasingly used in recent years, which also further explains the reasons behind this therapeutic area’s majority share of orphan drug approvals.

“Global Orphan Drug Pipeline & Regulatory Insight 2025” report gives comprehensive insight on clinical and non-clinical parameters related to development and commercialization of orphan drug market. As per report findings, there are more than 350 orphan designated drugs commercially available in the market and more than 900 in the clinical pipeline. Most of the orphan drugs in clinical pipeline are in Phase - II trials followed by Phase - III trials. More than 30 new orphan designated drugs are further expected to enter the market in next five years.

For Report Sample Contact: rajesh@pnspharma.com or +91-11-47067990

Download Report: http://www.pnspharma.com/buy-report.php?reporttitle=Global-Orphan-Drug-Pipeline-%26-Regulatory-Insight-2025

Report Table of Contents

1. Orphan Drugs: Regimens For Rare Diseases

2. Drivers of Orphan Drug Commercialization
2.1 Cost Aspects
2.2 Expiration of Patented Drugs
2.3 Economic & Non-Economic Incentives
2.4 Advantage of Patent & Market Exclusivity
2.5 High Investment in Research & Development

3. Global Orphan Drug Market Perspectives: Current Market Evaluations

4. Global Orphan Drug Market by Segmentation
4.1 Market by Class Variation
4.2 Market by Therapeutic Application
4.3 Market by Regions

5. Global Orphan Drug Clinical Pipeline Overview

6. Global Orphan Drug Designation Criteria
6.1 US
6.2 Europe
6.3 Asia & Australia
6.3.1 Japan
6.3.2 Taiwan
6.3.3 South Korea
6.3.4 Australia

7. Global Orphan Drug Reimbursement Policy
7.1 US
7.2 Europe
7.3 Asia

8. FDA Regulation for Clinical Trials Orphan Designated Drugs
8.1 Content & Format Of A Request For Written Recommendations
8.2 Provision For Granting & Refusing Written Recommendations
8.3 Content And Format Of A Request For Orphan Drug Designation
8.4 Verification Of Orphan Drug Status & Resident Agent For Foreign Sponsor
8.5 Timing Of Requests For Orphan Drug Designation & Designation Of Already Approved Drugs
8.6 Deficiency Letters And Granting Orphan Drug Designation
8.7 Refusal To Grant Orphan Drug Designation
8.8 Amendment & Change In Ownership To Orphan Drug Designation
8.9 Publication & Revocation Of Orphan Drug Designations
8.10 Annual Reports Of Holder Of Orphan Drug Designation
8.11 Scope & FDA Recognition Of Orphan Drug Exclusive Approval
8.12 Protocols for Investigations & Availability of Information

9. EMA Regulations for Clinical Trials of Orphan Designated Drugs
9.1 Committee for Orphan Medicinal Products
9.2 How to Apply for Orphan Designation in Europe
9.3 Marketing Authorization & Market Exclusivity
9.4 Transferring An Orphan Designation To Another Sponsor
9.5 Mandatory Submission Of Annual Report On Development
9.6 Incentives For Micro, Small And Medium-Sized Enterprises
9.7 Fee Reductions For Designated Orphan Medicinal Products
9.8 Procedure for Orphan Designation & Incentives for R&D ( Regulation (EC) No 141/2000 )

10. Asian Regulations for Clinical Trials of Orphan Designated Drugs
10.1 Taiwan Rare Disease and Orphan Drug Act
10.2 Japan Orphan Drug Regulation

11. Global Orphan Drug Clinical Pipeline by Company, Indication & Phase
11.1 Unknown
11.2 Research
11.3 Preclinical
11.4 Clinical
11.5 Phase-I
11.6 Phase-I/II
11.7 Phase-II
11.8 Phase-II/III
11.9 Phase-III
11.10 Preregistration
11.11 Registered

12. Marketed Global Orphan Drug Clinical Insight by Company & Indication

13. Competitive Landscape
13.1 AOP Orphan
13.2 Agenus
13.3 Alexion
13.4 Bristol Myers Squibb
13.5 Biogen Idec
13.6 Celgene
13.7 Eli Lilly
13.8 Genethon
13.9 Genzyme Corporation
13.10 Glaxosmithkline
13.11 Merck
13.12 Novartis Pharmaceuticals
13.13 Orphan Europe
13.14 Pfizer
13.15 Prosensa
13.16 Rare Disease Therapeutics
13.17 Roche
13.18 Sanofi
13.19 Shire
13.20 Teva Pharmaceutical

Figure 2-1: Orphan v/s Non-Orphan Drugs -Phase II to Launch Clinical Development Time
Figure 2-2: Probability of Regulatory Success of Orphan v/s Non-Orphan Drugs
Figure 3-1: Global - Orphan Drugs Market Value (US$ Billion), 2017-2025
Figure 3-2: US - Orphan Drugs Market Value (US$ Billion), 2017-2025
Figure 3-3: Europe - Orphan Drugs Market Value (US$ Billion), 2017-2025
Figure 3-4: Asia* Orphan Drugs Market Value (US$ Billion), 2017-2025
Figure 4-1: Biological & Non Biological Orphan Drug Segment (%), 2017 & 2025
Figure 4-2: Biological & Non Biological Orphan Drug Market (US$ Billion), 2017-2025
Figure 4-3: Global Orphan Drugs Market by Therapeutic Area, 2017 & 2025
Figure 4-4: Regional Markets for Orphan Drugs, 2017 & 2025
Figure 5-1: Global - Orphan Drug Clinical Pipeline by Phase (%), 2018 till 2025
Figure 5-2: Global - Orphan Drug Clinical Pipeline by Phase (Number), 2018 till 2025
Figure 5-3: US - Orphan Drugs Clinical Pipeline by Phase (%), 2018 till 2025
Figure 5-4: US - Orphan Drugs Clinical Pipeline by Phase (Number), 2018 till 2025
Figure 5-6: Europe - Orphan Drug Clinical Pipeline by Phase (%), 2018 till 2025
Figure 5-7: Europe - Orphan Drug Clinical Pipeline by Phase (Number), 2018 till 2025
Figure 10-1: Japan Orphan Drug/Medical Device Designation System
Figure 10-2: Japan Orphan Drug/Device Designation Process

Table 2-1: Orphan Drugs in the US and their Costs
Table 2-2: Orphan Drugs in the EU and their Costs
Table 2-3: Drugs Patent Expiry in 2014
Table 2-4: Drugs Patent Expiry in 2015
Table 2-5: Drugs Patent Expiry in 2016
Table 2-6: Drugs Patent Expiry, 2017-2022
Table 2-7: Orphan Drug Incentives by Country
Table 2-8: Incentives for the Development of Orphan Drugs

PNS Pharma is a pioneer in offering exclusive research reports for the pharmaceuticals industry. PNS Pharma offers Syndicated Research Reports on Drug Pipeline and Company Pipeline Analysis. These reports include comprehensive information related to the development of various drugs across clinical pipeline. Further, the reports include details on the originator, Owner, License, Chemical Formula, Patent Information, Phase of development, and Phase of development by country for each specific drug. The reports on company pipeline include all the drugs developed by particular companies across different therapeutic segments and phases and in different countries.

Rajesh Sharma
rajesh@pnspharma.com
PNS Pharma
New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.